Back to search

National and Kapodistrian University of Athens

Μελέτη κυτταρικών πληθυσμών μυελοδυσπλαστικών και μυελοδυσπλαστικών/μυελοϋπερπλαστικών συνδρόμων με κυτταρομετρία ροής και μοριακές τεχνικές: επικύρωση μεθόδου και συσχέτιση με άλλες κλινικοεργαστηριακές παραμέτρους

Abstract

dc:description

Background: The myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal haematological disorders characterised by dysplasia and ineffective haematopoiesis [1-3]. MDS patients carry an approximate 25% risk of progression to acute myeloid leukaemia [3]. The hallmark of MDS is morphologic dysplasia involving one or more bone marrow cell lineages. Although the diagnostic criteria for MDS are well established, a significant number of MDS patients display peripheral blood and bone marrow findings without robust diagnostic morphologic characteristics. In the proposed minimal essential criteria to meet the diagnosis of MDS, in International Working Conference in Vienna (2006) [1], bone marrow flow cytometric analysis was introduced as a useful co-criterion in cases where morphology and cytogenetics are equivocal. The use of flow cytometric data is not limited to diagnostic purposes only but may have potential prognostic value for the patients as well. Aim: The purpose of the study was the standardization and harmonization methodology and reagents in order to increase the general impact and awareness of this important approach to MDS, and to facilitate its use as a general standard in clinical practice. Material and Method: A) A 4-color-multiparametric flow cytometry with an extensive panel of monoclonal antibodies [CD3, CD4, CD5, CD7, CD10, CD11b, CD13, CD14, CD15, CD16, CD19, CD33, CD34, CD36, CD38, CD45, CD45RO, CD45RA, CD56, CD62L, CD64, CD79a, CD116, CD117, anti-HLA-DR, anti-KOR-SA, anti-MPO, anti-LF, anti-TCRγδ, 7AAD] in BM specimens of Controls (Ν=17) and patients with MDS (Ν=72), MDS/MPD (Ν=13) and MDS/AL (Ν=9) as well as in PB specimens of Controls (Ν=41) and patients with MDS (Ν=22), MDS/MPD (Ν=8) και MDS/AL (Ν=6) was used for patients immunophenotyping. All MDS and MDS/MPD patients were classified as lower-risk and higher-risk MDS, according to NCCN. B) Validation of leukocytes subsets immunophenotyping was also performed. C) Specimens with malignant populations (B-Chronic Lymphocytic Leukemia, Acute Myeloblastic Leukemia and Myelodysplastic Syndrome) were studied in order to evaluate the suitability of a blood stabilizing reagent (Transfix®) in routine laboratory practice. D) TCR Vβ (by FC) and TCR Vγ (by PCR) clonality investigation was performed in PB specimens, E) Oxidative burst and Phagocytosis tests were performed, by FC, in ΡΒ specimens and F) DNA analysis assessment, by FC, was performed in BM specimens. Results: The within day precision of the method (N=6) was found satisfactory concerning all leukocytes subpopulations. Checking the precision in four consecutive days, lymphocytes percentages reliability was verified until day 3, in all specimens. For blast cells, neutrophil granulocytes and monocytes the results were different in each specimen. The present study, in agreement with international guidelines, indicates that specimen preparation and determination of lymphocytes subsets should be carried out as soon as possible after patient’s venepuncture. Method accuracy was evaluated both through external quality assessment system as well as by comparing measurements of the same specimen in two different flow cytometers and found acceptable. Dilution 1:16 of control specimen was found appropriate to define method detection limit of leukocytes subsets, a very important consideration when specimen volume is limited. The present study indicates that TransFix® stabilizing reagent can be used reliably in flow cytometric analysis; light scatter characteristics and immunophenotype are well preserved in TransFix®-treated specimens stored at 4-100C particularly concerning the blasts and lymphocytes populations for 15 days. In case cells percentages are limited, specimen preparation must be accomplished as soon as possible (in less than 24h). Bone marrow leukocytes immunophenotype investigation in blasts of MDS, MDS/MPD, and MDS/AL patients, compared to controls showed: increase of CD34+ blast cells, CD33, CD13, CD117 expression decrease or absence, expression of CD7 and CD11b, as well as CD34+CD19+ Β cells percentages decrease. Most disturbances were observed in higher-risk MDS patients, showing the correlation between phenotypic disturbances and progression to AL. After a detailed comparative analysis of granulocytes immunophenotype in MDS/MPD and MDS patients no significant differences in antigen expression profiles were found between the two groups, therefore MDS/MPD patients were included in this study. The investigation of Total Neutrophil Granulocytes (TNG) population from MDS cases in comparison to the controls revealed phenotypic patterns of dysplasia such as the decreased MPO/LF, CD16/MPO and CD16/LF co-expression percentages in MDS TNG, in addition to the findings observed by other investigators. These aberrancies were characterise lower-risk and higher-risk MDS, as well, and reflect the maturational abnormalities of the granulocytic series in the bone marrow of MDS patients and can de used as additional markers for diagnostic purposes. The population of TNG from higher-risk MDS cases displayed abnormal expression of HLA-DR. Our findings emphasise the importance of identifying the two distinct subpopulations within the TNG gate which were analysed in the gates of dimCD45 (NGS A) and strongCD45 (NGS B) signal in a CD45-SSc-plot. Controls NGS A represents a cell “mixture” of different maturational stages whereas NGS B consists mainly of mature neutrophil granulocytes expressing CD10+, CD11b+, CD13+, CD16+, MPO+ και LF+, in high percentages. The NGS A in MDS is a cell “mixture” of different maturational stages with abnormalities such as a higher percentage of myelocytes and an absence of metamyelocytes and bands as revealed from the patterns. The analysis of CD16, HLA-DR and CD16/CD11b expressions in the NGS A gate offers a clearer distinction between controls, lower-risk and higher-risk MDS than gating TNG. The NGS B in MDS is a mature population having high CD10, CD13 but with dysplastic features such as aberrant expression of HLA-DR, and lower CD16, CD16/CD11b, MPO/LF, CD16/MPO, CD16/LF percentages which were identified in some individuals with lower-risk MDS especially when the NGS B was separately studied. We think that these findings are consistent with the dysplastic characteristics of these patients. The comparison of bone marrow lymphocytes immunophenotype between patients with MDS and controls, showed B cells percentages decreasing and progressively moving from controls to lowerrisk and to higher-risk MDS. Neutrophil granulocytes peripheral blood immunophenotype analysis, in patients with MDS, compared to controls, was characterized by CD15/CD13, CD15/CD16, sCD11b/CD16 and MPO/LF co-expression decrease. These disturbances are more prominent in patients with higher-risk MDS. Monocytes PB immunophenotype analysis, showed progressive decrease of CD14, HLA-DR expression and CD36/CD116, HLA-DR/CD13, HLA-DR/CD38, co-expression as well as increase of CD64/CD16 co-expression, in patients with lower-risk MDS to higher-risk MDS. These parameters cannot discriminate between lower-risk MDS and controls. In contrast, the pathological increase of CD117 (immaturity marker) and CD16 (granulocytes marker) could discriminate lower-risk MDS patients from the controls and patients with higher-risk MDS. Lymphocytes ΡΒ immunophenotype analysis, showed percentages disturbances, such as CD4+ T lymphocytes increase (especially in lower-risk MDS) and CD8+ T cells decrease (in lower-risk MDS and higher-risk MDS), compared to controls. CD38 (activation marker) was progressively increased moving from controls to lower-risk and to higher-risk MDS. TCR Vβ clonality study, by FC, showed different disturbances. However, monoclonality was not observed neither by flow cytometry nor by PCR. Phagocytes functionality investigation, by FC, in patients with MDS and MDS/MPD, showed decrease of oxidative burst capacity in granulocytes and monocytes, compared to controls. Phagocytosis capacity was decreased specifically in granulocytes. The abnormalities were more pronounced in patients with higher-risk MDS. Additionally, statistically important were the correlations of phagocytes oxidative burst capacity with immunophenotype findings of dysplasia in bone marrow TNG, NGSs and monocytes. Aneuploidy was observed in patients’ bone marrow myeloid cell lineage. Bone marrow lymphoid cell lineage S phase, was progressively decreased moving from controls to lower-risk and to higher-risk MDS. These findings correspond to the progressive increase of the blast cells percentage and therefore to the disease progression to AL. Conclusions: In the present study bone marrow was found the most appropriate specimen for MDS and MDS/MPD investigation, because of its important findings. These findings concerned mainly the neutrophil granulocytes. It seems that this lineage is the most affected leukocytic population, after blast cells, in MDS. This work indicated that the multicolor flow cytometric analysis of NGSs is a useful aid in diagnosing MDS, especially regarding lower-risk MDS patients. This observation is important because sometimes the immunophenotypic disturbances in TNG are minor and not obvious, whereas the separate examination of the two NGSs might reveal the dysplastic features that otherwise would have been missed. Therefore the NGSs phenotypic analysis (especially of the NGS B subpopulation) using specific markers and patterns of expression, as described, seems to offer a clear advantage for dysplasia screening. It is conceivable that our ability to estimate and follow-up minor and advancing dysplasia by flow cytometry could help substantially in the development of a diagnostic and prognostic tool for patients with MDS. Additionally, monocytes and lymphocytes findings could contribute in MDS and MDS/MPD diagnosis and patients monitoring. It is noted that whereas bone marrow is the most important specimen for MDS and MDS/MPD evaluation, leukocytes immunophenotype analysis, by FC, can be also accomplished in peripheral blood, especially in patients with disease progression. As a result of this study, a protocol was evaluated for the investigation of Myelodysplastic Syndromes and Myelodysplastic/Myeloproloferative Diseases, by flow cytometry. This protocol is suitable for application in every clinical flow cytometry laboratory, and can be used for BM and/or PB specimen analysis after venepuncture or even some days later (using Transfix®). It is an important diagnostic and patients monitoring tool, which can contribute in the patients quality of life amelioration.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2009

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Vikentiou, Myrofora
  • Βικεντίου, Μυροφόρα

Subjects

dc:subject × 24

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/27846

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Vikentiou, Myrofora; Βικεντίου, Μυροφόρα. Μελέτη κυτταρικών πληθυσμών μυελοδυσπλαστικών και μυελοδυσπλαστικών/μυελοϋπερπλαστικών συνδρόμων με κυτταρομετρία ροής και μοριακές τεχνικές: επικύρωση μεθόδου και συσχέτιση με άλλες κλινικοεργαστηριακές παραμέτρους. National and Kapodistrian University of Athens, 2009. http://hdl.handle.net/10442/hedi/27846